Welcome to our dedicated page for Lexeo Therapeutics news (Ticker: LXEO), a resource for investors and traders seeking the latest updates and insights on Lexeo Therapeutics stock.
Lexeo Therapeutics Inc (NASDAQ: LXEO) is a clinical-stage genetic medicine leader developing novel gene therapies for cardiovascular and neurological disorders. This page provides official updates on LXEO's research advancements, regulatory milestones, and strategic initiatives.
Investors and industry observers will find a comprehensive collection of press releases detailing clinical trial progress, partnership announcements, and financial disclosures. Our curated news feed covers LXEO's pioneering work in AAV-based therapies targeting Friedreich ataxia cardiomyopathy and APOE4-linked Alzheimer's disease.
Key updates include developments from LXEO's collaborations with academic institutions like Cornell University, FDA designation achievements, and pipeline expansion news. All content is sourced directly from company releases to ensure accuracy and timeliness.
Bookmark this page for streamlined access to LXEO's latest scientific breakthroughs and corporate announcements. Check regularly for updates on gene therapy trials and regulatory progress in this cutting-edge biotech sector.
Lexeo Therapeutics (NASDAQ: LXEO) announced it will present new data on its AAV manufacturing optimization at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) from May 13-17, 2025, in New Orleans. The company will showcase two presentations highlighting their Sf9-baculovirus manufacturing platform, which demonstrates improved scalability, reduced costs, and maintained purity and potency in AAV production.
The presentations include research on improving VP1 ratios' impact on CQAs in rh10 AAV manufacturing and the development of a novel high-yielding scalable platform capable of producing quality AAV at 200L scale. According to Chief Technical Officer José Manuel Otero, these advancements will help accelerate the company's clinical-stage gene therapy programs and mission to deliver transformative therapies to patients.
Lexeo Therapeutics (Nasdaq: LXEO) reported positive interim Phase 1/2 data for LX2006 in treating Friedreich ataxia (FA) cardiomyopathy. The trial showed significant improvements in cardiac measures, with participants achieving a 25% mean reduction in left ventricular mass index (LVMI) by 12 months.
Key findings include:
- 115% average cardiac frataxin expression increase in high dose cohort
- 27% mean improvement in LVMI at latest visit for participants with abnormal baseline LVMI
- 10 of 12 participants achieved reduction in lateral wall thickness
- 11 of 12 participants showed >25% reduction in high-sensitivity troponin I
The treatment was generally well-tolerated with no Grade 3+ SAEs. The company plans to initiate a registrational study by early 2026, with potential efficacy readout in 2027.
Lexeo Therapeutics (NASDAQ: LXEO) has reported its Q4 and full-year 2024 financial results, highlighting significant progress in its gene therapy programs. The company achieved further FDA alignment on LX2006's pivotal study for Friedreich ataxia cardiomyopathy, with protein expression to be evaluated for any increase from baseline.
Early data from the LX2020 HEROIC-PKP2 Phase 1/2 trial showed promising results, with 71% and 115% increases in PKP2 protein expression in the first two post-treatment biopsies. The first participant demonstrated a 67% reduction in premature ventricular contractions after 6 months.
Financial highlights include:
- Cash position of $128.5 million, providing runway into 2027
- Q4 2024 R&D expenses of $18.4 million vs $8.2 million in Q4 2023
- Q4 2024 net loss of $25.9 million ($0.78 per share)
- Full-year 2024 net loss of $98.3 million ($3.09 per share)
Lexeo Therapeutics (Nasdaq: LXEO), a clinical stage genetic medicine company focusing on genetically defined cardiovascular diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. R. Nolan Townsend, the company's CEO, will deliver a presentation on Wednesday, January 15, 2025 at 8:15 AM PT in San Francisco, California.
The presentation will be accessible through a live webcast in the News & Events tab of the Investors section on the company's website. A replay option will be made available following the presentation for those unable to attend the live session.
Lexeo Therapeutics (Nasdaq: LXEO) has appointed Dr. Kyle Rasbach as Chief Financial Officer, effective immediately. Dr. Rasbach joins the clinical stage genetic medicine company with extensive experience in life sciences, including roles as Chief Business Officer at Zentalis Pharmaceuticals and Portfolio Manager at Eventide Asset Management's $1.8 billion healthcare & life sciences fund.
Prior positions include Managing Partner at Pappas Capital, Vice President at T. Rowe Price managing over $40 billion in investments, and Vice President at Cowen and Company. Dr. Rasbach holds a PhD in Pharmaceutical and Biomedical Sciences, a PharmD, and an MBA, joining Lexeo ahead of multiple anticipated catalysts across its gene therapy programs.
Satellos Bioscience (TSX:MSCL, OTCQB:MSCLF) announces participation in a live investor webinar focused on Duchenne muscular dystrophy (DMD) on December 4, 2024, at 2:00 pm ET. The webinar will feature key opinion leaders discussing three main topics: new treatment approaches for DMD, patient navigation of clinical trials, and Satellos' novel small molecule approach focusing on muscle regeneration.
Featured speakers include Elijah Stacy, a DMD patient advocate and Founder of Destroy Duchenne, Dr. Michael Rudnicki, Scientific Founder of Satellos and Director of Regenerative Medicine at Ottawa Hospital Research Institute, and Dr. Jordan Dubow, Satellos' CMO. The event will include a Q&A session and is free to attend.
Lexeo Therapeutics (NASDAQ: LXEO) reported key developments and Q3 2024 financial results. The company reached FDA alignment on registrational endpoints for LX2006 and received RMAT designation for treating Friedreich ataxia cardiomyopathy. Enrollment was completed for the LX2006 SUNRISE-FA Phase 1/2 trial and cohort 1 of LX2020 HEROIC-PKP2 trial. Financial highlights include cash position of $157.0 million expected to fund operations into 2027, R&D expenses of $23.4 million, and a net loss of $29.5 million ($0.89 per share) for Q3 2024.
Lexeo Therapeutics announced positive interim results from their Phase 1/2 study of LX1001, a gene therapy for APOE4-associated Alzheimer's disease. The therapy demonstrated dose-dependent increases in neuroprotective APOE2 protein expression and improvements in AD-associated tau biomarkers. The study, which enrolled fifteen patients with mild cognitive impairment or mild/moderate AD, showed consistent reductions in CSF tau biomarkers and tau PET in most participants. LX1001 exhibited a favorable safety profile with no reports of amyloid-related imaging abnormalities (ARIA). Notably, participants with moderate AD showed the most improvement across various biomarker endpoints.
Lexeo Therapeutics (Nasdaq: LXEO) will present interim data from its Phase 1/2 trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy designed to deliver the protective APOE2 gene to APOE4 homozygotes with Alzheimer's disease.
The trial, which completed enrollment in Q4 2023, evaluates safety and tolerability in 15 patients with Alzheimer's disease and two copies of the APOE4 allele. The presentation will review safety and efficacy measures, including protein expression and tau and amyloid biomarkers. It will feature 12-month data for Cohorts 1-3 and 6-month data for Cohort 4.
Lexeo Therapeutics (Nasdaq: LXEO), a clinical stage genetic medicine company, has announced its participation in several upcoming investor conferences. The company, which focuses on developing treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, will be presenting at four major healthcare and investment events in September and October 2024:
- H.C. Wainwright 26th Annual Global Investment Conference on September 9
- Baird 2024 Global Healthcare Conference on September 10
- Cantor 2024 Global Healthcare Conference on September 18
- Chardan's 8th Annual Genetic Medicines Conference on October 1
All presentations will be webcast live and available for replay on the company's website under the Investors section.
FAQ
What is the current stock price of Lexeo Therapeutics (LXEO)?
What is the market cap of Lexeo Therapeutics (LXEO)?
